Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | IKBKB | O14920 | 2/20 | 0.54 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.54 |
| ▸ | DHFR | P00374 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metoprine SCHEMBL3681 | 1.00 | NPC1 (0.54) | NPC1RAB9AIKBKBMAP3K14DHFR | |
| Metoprine SCHEMBL4529657 | 0.98 | NPC1 (0.53) | NPC1RAB9AIKBKBMAP3K14DHFR | |
| SCHEMBL10999078 | 0.89 | ALDH1A1 (0.48) | NPC1RAB9AIKBKBMAP3K14DHFR | |
| SCHEMBL4535505 | 0.83 | HRH4 (0.47) | DHFRKMO | |
| SCHEMBL7271200 | 0.83 | HEXA (0.42) | NPC1RAB9ADHFRTP53CYP1A2 | |
| SCHEMBL7271143 | 0.83 | HEXA (0.42) | NPC1RAB9ADHFRTP53CYP1A2 | |
| SCHEMBL6049552 | 0.81 | IKBKB (0.49) | NPC1RAB9AIKBKBMAP3K14DHFR | |
| SCHEMBL11593238 | 0.81 | KMT2A (0.63) | NPC1RAB9AIKBKBMAP3K14DHFR | |
| SCHEMBL9485648 | 0.80 | NCOA1 (0.72) | DHFRTP53CYP1A2CYP3A4CYP2D6 | |
| Etoprine SCHEMBL3919 | 0.80 | DHFR (0.70) | DHFRTP53CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| US-20220304972-A1 | COMBINATION THERAPY AND BIOMARKER INDICATING EFFICACY THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-09-29 | — | — | US | disclosed |
| CN-114375310-A | Several heterodimers and several methods of use thereof | 卡尔医学有限公司 | 2022-04-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220304972-A1 | COMBINATION THERAPY AND BIOMARKER INDICATING EFFICACY THEREOF | MSH2, PMS2, MSH6 | NPC1 3578/4885RAB9A 4628/4885IKBKB 466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.